Rhythm Pharmaceuticals 将公布评估 Setmelanotide 在普瑞德-威利综合征患者中的六个月中期二期试验结果

美股速递
Jun 13

Rhythm Pharmaceuticals Inc. 即将公布其药物 Setmelanotide 用于治疗普瑞德-威利综合征患者的二期临床试验中期结果。此次公布的数据将涵盖为期六个月的研究阶段。

该消息备受市场关注,因 Setmelanotide 的疗效数据可能对公司的未来前景产生重要影响。投资者正密切关注试验结果,以评估该疗法在应对这一罕见遗传性疾病方面的潜力与进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10